PREVIOUS
✖
CORBEVAX
September 8 , 2021
1103 days
1022
0
- The Drug Controller General of India (DCGI) gave approval to another indigenous COVID-19 vaccine candidate called CORBEVAX for two clinical trials.
- This vaccine is also called as BioE COVID-19 vaccine.
- This COVID-19 vaccine candidate has been developed by Indian bio pharmaceutical firm Biological E. Limited (BioE) in collaboration with the Baylor College of Medicine, Houston in the United States and the American company Dynavax Technologies (DVAX).
- This Vaccine is a protein subunit vaccine.
- Biological E received approval to conduct phase two and three clinical trials on children between five to eighteen years of age.
- The vaccine has also received financial assistance under Mission COVID Suraksha and a financial support under COVID-19 Research Consortia through National Biopharma Mission, BIRAC.
Leave a Reply
Your Comment is awaiting moderation.